RecruitingType 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Eligible age
18–75 yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
Sponsor: Biomea Fusion Inc.
Where it's recruiting
Alabama
Birmingham
California
Canoga Park · Long Beach · Montclair · San Diego
Florida
Fort Myers · Miami Lakes · Winter Park
Georgia
Columbus · Cordele
Nevada
Las Vegas
North Carolina
Morehead City
Ohio
Canton
Texas
Austin · Dallas · Houston · Lewisville …
Virginia
Burke
Source: ClinicalTrials.gov · NCT07502508 · last updated 2026-10-20